NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients with R/R B-ALL
Dr. Christian Itin, Autolus Chief Executive Officer, said: “We believe AUCATZYL represents an important new treatment option for eligible adult r/r B-ALL patients. NHS clinical centres and UK patients participated in the development of AUCATZYL and we are looking forward to supporting patients and physicians in England and Wales now with the commercial product.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.